- Home
- XPRO vs GENB Comparison
XPRO vs GENB Comparison
Compare XPRO & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | XPRO | GENB |
|---|---|---|
| Founded | 1938 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | XPRO | GENB |
|---|---|---|
| Price | $15.46 | $14.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $16.00 | ★ $23.20 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $522,493,000.00 | N/A |
| Revenue This Year | $1.86 | N/A |
| Revenue Next Year | $4.70 | $16.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.89 | N/A |
| 52 Week Low | $8.24 | $11.00 |
| 52 Week High | $18.73 | $18.18 |
Technical Indicators
Market Signals| Indicator | XPRO | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 45.42 |
| Support Level | $12.80 | $11.73 |
| Resistance Level | $17.11 | $15.05 |
| Average True Range (ATR) | 0.57 | 1.25 |
| MACD | 0.17 | -0.17 |
| Stochastic Oscillator | 97.77 | 13.29 |
Price Performance
Historical ComparisonAbout XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.
About GENB Generate Biomedicines Inc. Common Stock
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.